Analyzing Kyowa Kirin (KYKOF) and The Competition

Kyowa Kirin (OTCMKTS:KYKOF) is one of 906 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Kyowa Kirin to similar companies based on the strength of its risk, institutional ownership, analyst recommendations, earnings, dividends, profitability and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Kyowa Kirin and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyowa Kirin	1	0	0	0	1.00
Kyowa Kirin Competitors	7710	13654	25543	992	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 30.32%. Given Kyowa Kirin’s competitors stronger consensus rating and higher probable upside, analysts clearly believe Kyowa Kirin has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Kyowa Kirin and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyowa Kirin	N/A	N/A	0.42
Kyowa Kirin Competitors	$3.57 billion	$3.15 billion	542.58

Kyowa Kirin’s competitors have higher revenue and earnings than Kyowa Kirin. Kyowa Kirin is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Dividends

Kyowa Kirin pays an annual dividend of $19.94 per share and has a dividend yield of 138.2%. Kyowa Kirin pays out 58.1% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.7% and pay out 48.3% of their earnings in the form of a dividend.

Insider & Institutional Ownership

10.3% of Kyowa Kirin shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.0% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Kyowa Kirin and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyowa Kirin	N/A	N/A	N/A
Kyowa Kirin Competitors	-2,303.77%	-221.68%	-17.78%

Summary

Kyowa Kirin competitors beat Kyowa Kirin on 9 of the 13 factors compared.

Kyowa Kirin Company Profile

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.